Two ex-blue­bird lead­ers launch Nvel­op with $100M to tack­le the biggest prob­lem in gene edit­ing

Nvel­op Ther­a­peu­tics launched Tues­day with $100 mil­lion in seed fund­ing to ad­vance re­search from the gene edit­ing pi­o­neers David Liu and Kei­th Joung, as they try to tack­le the field’s biggest prob­lem.

The Cam­bridge, MA start­up is the lat­est com­pa­ny to seek bet­ter ways to de­liv­er pow­er­ful gene-mod­i­fy­ing tools like CRISPR/Cas9, base edit­ing and prime edit­ing. While these edit­ing sys­tems hold vast po­ten­tial, they’ve been held back by a lack of op­tions to pack­age them and get them to the right places in the body.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER